Radiosensitization of Hs-766T pancreatic tumor xenografts in mice dosed with dodecafluoropentane nano-emulsion-preliminary findings

Jennifer L H Johnson, Rafael A. Leos, Amanda F Baker, Evan C Unger

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Tumor hypoxia is an important mediator of radiation therapy resistance. We conducted a study to investigate whether an oxygen therapeutic based upon dodecafluoropentane (DDFP) nano-emulsion (NVX-108) could increase tumor pO2 in hypoxic tumors and improve radiation response. Pancreatic (Hs-766T) tumor xenografts were grown in the flanks of 29 SCID mice. Direct tumor pO2 measurements were performed in 9 mice treated with 0.3, 0.45 and 0.6 cc/kg NVX-108 (2% w/vol DDFP) in order to assess the dose dependent increase in tumor pO2. Twenty mice were randomized into 3 groups including control (no treatment), carbogen breathing treated with 12 Gy radiation, and carbogen breathing treated with 12 Gy radiation and NVX-108 (0.6 cc/kg NVX-108 administered as 30 minute IV infusion at time of radiation). Tumor volume was monitored to assess treatment efficacy. Results showed that tumor pO2 increased in NVX-108 treated mice up to 400% with the greatest effect seen at the highest dose of 0.6 cc/kg. Tumor growth was significantly reduced in both treatment groups relative to controls (p < 0.0001). The combination of carbogen, radiation, and NVX-108 demonstrated a 2-fold reduction in average tumor volume compared to carbogen plus radiation treatment (p = 0.01). Further study of NVX-108 as a radiation sensitizer is warranted.

Original languageEnglish (US)
Pages (from-to)274-281
Number of pages8
JournalJournal of Biomedical Nanotechnology
Volume11
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Emulsions
Heterografts
Tumors
Radiation
Neoplasms
Radiation Dosage
Tumor Burden
Respiration
Radiation-Sensitizing Agents
SCID Mice
Therapeutics
perfluoropentane
Radiotherapy
Oxygen
Control Groups
carbogen
Growth

Keywords

  • Dodecafluoropentane
  • Nano-emulsion
  • Oxygen therapeutic
  • Radiation
  • Radioensitization
  • Tumor hypoxia

ASJC Scopus subject areas

  • Materials Science(all)
  • Bioengineering
  • Biomedical Engineering
  • Medicine (miscellaneous)
  • Pharmaceutical Science

Cite this

Radiosensitization of Hs-766T pancreatic tumor xenografts in mice dosed with dodecafluoropentane nano-emulsion-preliminary findings. / Johnson, Jennifer L H; Leos, Rafael A.; Baker, Amanda F; Unger, Evan C.

In: Journal of Biomedical Nanotechnology, Vol. 11, No. 2, 01.02.2015, p. 274-281.

Research output: Contribution to journalArticle

@article{9065795fcabb4260848fd766a69a9c70,
title = "Radiosensitization of Hs-766T pancreatic tumor xenografts in mice dosed with dodecafluoropentane nano-emulsion-preliminary findings",
abstract = "Tumor hypoxia is an important mediator of radiation therapy resistance. We conducted a study to investigate whether an oxygen therapeutic based upon dodecafluoropentane (DDFP) nano-emulsion (NVX-108) could increase tumor pO2 in hypoxic tumors and improve radiation response. Pancreatic (Hs-766T) tumor xenografts were grown in the flanks of 29 SCID mice. Direct tumor pO2 measurements were performed in 9 mice treated with 0.3, 0.45 and 0.6 cc/kg NVX-108 (2{\%} w/vol DDFP) in order to assess the dose dependent increase in tumor pO2. Twenty mice were randomized into 3 groups including control (no treatment), carbogen breathing treated with 12 Gy radiation, and carbogen breathing treated with 12 Gy radiation and NVX-108 (0.6 cc/kg NVX-108 administered as 30 minute IV infusion at time of radiation). Tumor volume was monitored to assess treatment efficacy. Results showed that tumor pO2 increased in NVX-108 treated mice up to 400{\%} with the greatest effect seen at the highest dose of 0.6 cc/kg. Tumor growth was significantly reduced in both treatment groups relative to controls (p < 0.0001). The combination of carbogen, radiation, and NVX-108 demonstrated a 2-fold reduction in average tumor volume compared to carbogen plus radiation treatment (p = 0.01). Further study of NVX-108 as a radiation sensitizer is warranted.",
keywords = "Dodecafluoropentane, Nano-emulsion, Oxygen therapeutic, Radiation, Radioensitization, Tumor hypoxia",
author = "Johnson, {Jennifer L H} and Leos, {Rafael A.} and Baker, {Amanda F} and Unger, {Evan C}",
year = "2015",
month = "2",
day = "1",
doi = "10.1166/jbn.2015.1903",
language = "English (US)",
volume = "11",
pages = "274--281",
journal = "Journal of Biomedical Nanotechnology",
issn = "1550-7033",
publisher = "American Scientific Publishers",
number = "2",

}

TY - JOUR

T1 - Radiosensitization of Hs-766T pancreatic tumor xenografts in mice dosed with dodecafluoropentane nano-emulsion-preliminary findings

AU - Johnson, Jennifer L H

AU - Leos, Rafael A.

AU - Baker, Amanda F

AU - Unger, Evan C

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Tumor hypoxia is an important mediator of radiation therapy resistance. We conducted a study to investigate whether an oxygen therapeutic based upon dodecafluoropentane (DDFP) nano-emulsion (NVX-108) could increase tumor pO2 in hypoxic tumors and improve radiation response. Pancreatic (Hs-766T) tumor xenografts were grown in the flanks of 29 SCID mice. Direct tumor pO2 measurements were performed in 9 mice treated with 0.3, 0.45 and 0.6 cc/kg NVX-108 (2% w/vol DDFP) in order to assess the dose dependent increase in tumor pO2. Twenty mice were randomized into 3 groups including control (no treatment), carbogen breathing treated with 12 Gy radiation, and carbogen breathing treated with 12 Gy radiation and NVX-108 (0.6 cc/kg NVX-108 administered as 30 minute IV infusion at time of radiation). Tumor volume was monitored to assess treatment efficacy. Results showed that tumor pO2 increased in NVX-108 treated mice up to 400% with the greatest effect seen at the highest dose of 0.6 cc/kg. Tumor growth was significantly reduced in both treatment groups relative to controls (p < 0.0001). The combination of carbogen, radiation, and NVX-108 demonstrated a 2-fold reduction in average tumor volume compared to carbogen plus radiation treatment (p = 0.01). Further study of NVX-108 as a radiation sensitizer is warranted.

AB - Tumor hypoxia is an important mediator of radiation therapy resistance. We conducted a study to investigate whether an oxygen therapeutic based upon dodecafluoropentane (DDFP) nano-emulsion (NVX-108) could increase tumor pO2 in hypoxic tumors and improve radiation response. Pancreatic (Hs-766T) tumor xenografts were grown in the flanks of 29 SCID mice. Direct tumor pO2 measurements were performed in 9 mice treated with 0.3, 0.45 and 0.6 cc/kg NVX-108 (2% w/vol DDFP) in order to assess the dose dependent increase in tumor pO2. Twenty mice were randomized into 3 groups including control (no treatment), carbogen breathing treated with 12 Gy radiation, and carbogen breathing treated with 12 Gy radiation and NVX-108 (0.6 cc/kg NVX-108 administered as 30 minute IV infusion at time of radiation). Tumor volume was monitored to assess treatment efficacy. Results showed that tumor pO2 increased in NVX-108 treated mice up to 400% with the greatest effect seen at the highest dose of 0.6 cc/kg. Tumor growth was significantly reduced in both treatment groups relative to controls (p < 0.0001). The combination of carbogen, radiation, and NVX-108 demonstrated a 2-fold reduction in average tumor volume compared to carbogen plus radiation treatment (p = 0.01). Further study of NVX-108 as a radiation sensitizer is warranted.

KW - Dodecafluoropentane

KW - Nano-emulsion

KW - Oxygen therapeutic

KW - Radiation

KW - Radioensitization

KW - Tumor hypoxia

UR - http://www.scopus.com/inward/record.url?scp=84918532538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918532538&partnerID=8YFLogxK

U2 - 10.1166/jbn.2015.1903

DO - 10.1166/jbn.2015.1903

M3 - Article

C2 - 26349303

AN - SCOPUS:84918532538

VL - 11

SP - 274

EP - 281

JO - Journal of Biomedical Nanotechnology

JF - Journal of Biomedical Nanotechnology

SN - 1550-7033

IS - 2

ER -